A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress

Oncogene

Volumn 32, Issue 6, 2013, Pages 788-796

  Brooks, K ^a   Oakes, V ^a   Edwards, B ^a   Ranall, M ^a   Leo, P ^a   Pavey, S ^a   Pinder, A ^a   Beamish, H ^a   Mukhopadhyay, P ^a   Lambie, D ^b   Gabrielli, B ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Chk1; melanoma; replicative stress

Indexed keywords

AR 323; AR 678; CHECKPOINT KINASE 1; DIMETHYL SULFOXIDE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINESIS; CYTOSTASIS; CYTOTOXICITY; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MELANOMA; MELANOMA CELL; MITOSIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; S PHASE; STRESS, PHYSIOLOGICAL;

EID: 84873739385     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.72     Document Type: Article

References (41)

1. McDonald 3rd ER, El-Deiry WS. Checkpoint genes in cancer. Ann Med 2001; 33: 113-122.
2. Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 2003; 24: 139-145.
3. Lazzaro F, Giannattasio M, Puddu F, Granata M, Pellicioli A, Plevani P et al. Checkpoint mechanisms at the intersection between DNA damage and repair. DNA Repair (Amst) 2009; 8: 1055-1067.
4. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-698.
5. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010; 16: 376-383.
6. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000; 14: 1448-1459.
7. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7: 195-201.
8. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007; 8: 735-748.
9. Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 2000; 14: 397-402.
10. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev 2000; 14: 1439-1447.
11. Ge XQ, Blow JJ. Chk1 inhibits replication factory activation but allows dormant origin firing in existing factories. J Cell Biol 2010; 191: 1285-1297.
12. Petermann E, Woodcock M, Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci USA 2010; 107: 16090-16095.
13. Kramer A, Mailand N, Lukas C, Syljuasen RG, Wilkinson CJ, Nigg EA et al. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat Cell Biol 2004; 6: 884-891.
14. Loffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Kramer A. Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle 2006; 5: 2543-2547.
15. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011; 17: 88-96.
16. Kuntz K, O'Connell MJ. The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer? Cancer Biol Ther 2009; 8: 1433-1439.
17. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70: 4972-4981.
18. Chen MS, Ryan CE, Piwnica-Worms H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol 2003; 23: 7488-7497.
19. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005; 25: 3553-3562.
20. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973-977.
21. Lainchbury M, Collins I. Checkpoint kinase inhibitors: a patent review (2009-2010). Expert Opin Ther Pat 2011; 21: 1191-1210.
22. Davies KD, Humphries MJ, Sullivan FX, von Carlowitz I, Le Huerou Y, Mohr PJ et al. Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo. Oncol Res 2011; 19: 349-363.
23. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 2003; 33: 497-501.
24. Niida H, Tsuge S, Katsuno Y, Konishi A, Takeda N, Nakanishi M. Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J Biol Chem 2005; 280: 39246-39252.
25. Tang J, Erikson RL, Liu X. Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1). Proc Natl Acad Sci USA 2006; 103: 11964-11969.
26. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004; 23: 6693-6701.
27. McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y et al. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 2010; 9: 995-1004.
28. Gabrielli BG, De Souza CP, Tonks ID, Clark JM, Hayward NK, Ellem KA. Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci 1996; 109: 1081-1093.
29. Peddibhotla S, Lam MH, Gonzalez-Rimbau M, Rosen JM. The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis. Proc Natl Acad Sci USA 2009; 106: 5159-5164.
30. Nitta M, Kobayashi O, Honda S, Hirota T, Kuninaka S, Marumoto T et al. Spindle checkpoint function is required for mitotic catastrophe induced by DNAdamaging agents. Oncogene 2004; 23: 6548-6558.
31. Gabrielli B, Chau YQ, Giles N, Harding A, Stevens F, Beamish H. Caffeine promotes apoptosis in mitotic spindle checkpoint-arrested cells. J Biol Chem 2007; 282: 6954-6964.
32. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23: 2825-2837.
33. Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res 2007; 67: 339-345.
34. Myers K, Gagou ME, Zuazua-Villar P, Rodriguez R, Meuth M. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet 2009; 5: e1000324.
35. Sidi S, Sanda T, Kennedy RD, Hagen AT, Jette CA, Hoffmans R et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 2008; 133: 864-877.
36. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. Oncogeneinduced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633-637.
37. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001; 20: 1803-1815.
38. Wasco MJ, Pu RT, Yu L, Su L, Ma L. Expression of gamma-H2AX in melanocytic lesions. Hum Pathol 2008; 39: 1614-1620.
39. Wang XQ, Gabrielli BG, Milligan A, Dickinson JL, Antalis TM, Ellem KA. Accumulation of p16CDKN2A in response to ultraviolet irradiation correlates with late S-G(2)-phase cell cycle delay. Cancer Res 1996; 56: 2510-2514.
40. Stevens FE, Beamish H, Warrener R, Gabrielli B. Histone deacetylase inhibitors induce mitotic slippage. Oncogene 2008; 27: 1345-1354.
41. Ranall MV, Gabrielli BG, Gonda TJ. Adaptation and validation of DNA synthesis detection by fluorescent dye derivatization for high-throughput screening. Biotechniques 2010; 48: 379-386.